» Articles » PMID: 33876511

Prevalence and Prognostic Impact of Physical Frailty in Interstitial Lung Disease: A Prospective Cohort Study

Overview
Journal Respirology
Specialty Pulmonary Medicine
Date 2021 Apr 20
PMID 33876511
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: Physical frailty is associated with increased mortality and hospitalizations in older adults. We describe the prevalence of physical frailty and its prognostic impact in patients with a spectrum of fibrotic interstitial lung disease (ILD).

Methods: Patients with fibrotic ILD at the McMaster University ILD programme were prospectively followed up from November 2015 to March 2020. Baseline data were used to classify patients as non-frail (score = 0), pre-frail (score = 1-2) or frail (score = 3-5) based on modified Fried physical frailty criteria. The association between physical frailty and mortality was assessed using time-to-event models, adjusted for age, sex, lung function and diagnosis using the ILD Gender-Age-Physiology (ILD-GAP) score.

Results: We included 463 patients (55% male, mean [SD] age 68 [11] years); 82 (18%) were non-frail, 258 (56%) pre-frail and 123 (26%) frail. The most common ILD diagnoses were idiopathic pulmonary fibrosis (n = 183, 40%) and connective tissue disease-associated-ILD (n = 79, 17%). Mean time since diagnosis was 2.7 ± 4.6 years. There were 56 deaths within the median follow-up of 1.71 (interquartile range [IQR] 1.24, 2.31) years. Both frail and pre-frail individuals had a higher risk of death compared to those categorized as non-frail at baseline (adjusted hazard ratio [aHR] 4.14, 95% CI 1.27-13.5 for pre-frail and aHR 4.41, 95% CI 1.29-15.1 for frail).

Conclusion: Physical frailty is prevalent in patients with ILD and is independently associated with an increased risk of death. Assessment of physical frailty provides additional prognostic value to recognized risk scores such as the ILD-GAP score, and may present a modifiable target for intervention.

Citing Articles

Sarcopenia in interstitial lung disease.

Sheehy R, McCormack S, Fermoyle C, Corte T Eur Respir Rev. 2024; 33(174).

PMID: 39631931 PMC: 11615663. DOI: 10.1183/16000617.0126-2024.


Interstitial Pneumonia with Autoimmune Features: Aiming to Define, Refine, and Treat.

Joerns E, Sparks J Rev Colomb Reumatol. 2024; 31(Suppl 1):S45-S53.

PMID: 39399289 PMC: 11469586. DOI: 10.1016/j.rcreu.2023.07.006.


Incidence Rates of Infections in Rheumatoid Arthritis Patients Treated with Janus Kinase or Interleukin-6 Inhibitors: Results of a Retrospective, Multicenter Cohort Study.

Yoshida S, Miyata M, Suzuki E, Kanno T, Sumichika Y, Saito K J Clin Med. 2024; 13(10).

PMID: 38792541 PMC: 11122599. DOI: 10.3390/jcm13103000.


Clinical implications of frailty assessed in hospitalized patients with acute-exacerbation of interstitial lung disease.

Van Hollebeke M, Chohan K, Adams C, Fisher J, Shapera S, Fidler L Chron Respir Dis. 2024; 21:14799731241240786.

PMID: 38515270 PMC: 10958799. DOI: 10.1177/14799731241240786.


Lung function and the risk of frailty in the European population: a mendelian randomization study.

Zhou R, Tian G, Guo X, Li R Eur J Med Res. 2024; 29(1):95.

PMID: 38297347 PMC: 10832278. DOI: 10.1186/s40001-024-01685-y.